Clinical update on the use of moxifloxacin in the treatment of community-acquired complicated intraabdominal infections

Surgical Infections

Volumn 11, Issue 5, 2010, Pages 487-494

  Cheadle, William ^a,b   Lee, James T ^c   Napolitano, Lena M ^d   Nichols, Ronald Lee ^e  

^a University of Louisville School of Medicine   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; CILASTATIN; CIPROFLOXACIN; CLINDAMYCIN; GATIFLOXACIN; IMIPENEM; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ABDOMINAL PAIN; ANTIMICROBIAL ACTIVITY; APPENDICITIS; AREA UNDER THE CURVE; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; COMMUNITY ACQUIRED COMPLICATED INTRAABDOMINAL INFECTION; COMMUNITY ACQUIRED COMPLICATED INTRAABDOMOINAL INFECTION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; DIVERTICULITIS; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TISSUE LEVEL; DRUG TOLERABILITY; DRUG WITHDRAWAL; GASTROINTESTINAL SURGERY; HUMAN; HYPOKALEMIA; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; NAUSEA; NONHUMAN; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SINGLE DRUG DOSE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; BACTERIAL INFECTIONS; COMMUNITY-ACQUIRED INFECTIONS; HUMANS; PERITONITIS; QUINOLINES;

EID: 77957586002     PISSN: 10962964     EISSN: None     Source Type: Journal    
DOI: 10.1089/sur.2009.062     Document Type: Review

References (80)

1. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated intraabdominal infections. Clin Infect Dis 2003;37:997-1005.
2. Liu CD, McFadden DW. Acute abdomen and appendix. In: Surgery: Scientific Principles and Practice, 2nd edition. Greenfield LJ, Mulholland MW, Oldham KT, et al. (eds.). Philadelphia: Lippincott-Raven Publishers, 1997, pp. 1246-1261.
3. Food and Drug Administration. Clinical development and labeling of anti-infective drug products. Available at www.fda.gov/CDER/guidance/infections. htm#uncomplicated% 20intra-abdominal%20infections, accessed June 6, 2008.
4. Mazuski JE, Sawyer RG, Nathens AB, et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: An executive summary. Surg Infect 2002;3:161-173.
5. Blot S, De Waele JJ. Critical issues in the clinical management of complicated intra-abdominal infections. Drugs 2005;65:1611-1620.
6. Evans HL, Raymond DP, Pelletier SJ, et al. Diagnosis of intra-abdominal infection in the critically ill patient. Curr Opin Crit Care 2001;7:117-121.
7. Goldstein EJ. Intra-abdominal anaerobic infections: Bacteriology and therapeutic potential of newer antimicrobial carbapenem, fluoroquinolone, and desfluoroquinolone therapeutic agents. Clin Infect Dis 2002;35(suppl 1):S106-S111.
8. Goldstein EJ, Snydman DR. Intra-abdominal infections: Review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J Antimicrob Chemother 2004;53(suppl 2):ii29-ii36.
9. Solomkin JS, Hemsell DL, Sweet R, et al. Evaluation of new anti-infective drugs for the treatment of intraabdominal infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992;15(suppl 1):S33-S42.
10. Solomkin JS, Goldstein EJC, Stollman NH, et al. The role of moxifloxacin in the management of complicated intraabdominal infections. Infect Dis Clin North Am 2007;21(suppl 1):16-24.
11. Nathens AB, Rotstein OD. Antimicrobial therapy for intraabdominal infection. Am J Surg 1996;172(suppl 6A):1S-6S.
12. Brismar B, Nord CE. Monobactams and carbapenems for treatment of intraabdominal infections. Infection 1999;27:136-147.
13. Addiss DG, Shaffer N, Fowler BS, Tauxe RV. The epidemiology of appendicitis and appendectomy in the United States. Am J Epidemiol 1990;132:910-925.
14. McCaig LF, Nghi L. National hospital ambulatory medical care survey: 2000 emergency department summary. Advance data. CDC 2002;316: April 22.
15. Graff L, Russell J, Seashore J, et al. False-negative and falsepositive errors in abdominal pain evaluation: Failure to diagnose acute appendicitis and unnecessary surgery. Acad Emerg Med 2000;7:1244-1255.
16. Naoum JJ, Mileski WJ, Daller JA, et al. The use of abdominal computed tomography scan decreases the frequency of misdiagnosis in cases of suspected appendicitis. Am J Surg 2002;184:587-589.
17. Craig S. Appendicitis acute. In: Emedicine From WebMD. Lober W (ed.). Available at www.emedicine.com/emerg/topic41.htm, accessed September 12, 2007.
18. Huang E. Complications of appendectomy, colon, and rectal surgery. In: Complications in Surgery. Mulholland MW, Doherty GM (eds.). Philadelphia: Lippincott Williams & Wilkins, 2006, pp. 498-521.
19. Mueller MH, Glatzle J, Kasparek MS, et al. Long-term outcome of conservative treatment in patients with diverticulitis of the sigmoid colon. Eur J Gastroenterol Hepatol 2005;17:649-654.
20. Parks TG. Natural history of diverticular disease of the colon. Clin Gastroenterol 1975;4:53-69.
21. Kaiser AM, Jiang JK, Lake JP, et al. The management of complicated diverticulitis and the role of computed tomography. Am J Gastroenterol 2005;100:910-917.
22. Dominguez EP, Sweeney JF, Choi YU. Diagnosis and management of diverticulitis and appendicitis. Gastroenterol Clin North Am 2006;35:367-391.
23. Brook I, Frazier EH. Aerobic and anaerobic microbiology of retroperitoneal abscesses. Clin Infect Dis 1998;26:938-941. (Pubitemid 28180333)
24. Schein M. Surgical management of intra-abdominal infection: Is there any evidence? Langenbecks Arch Surg 2002;387:1-7.
25. van Goor H, Hulsebos RG, Bleichrodt RP. Complications of planned relaparotomy in patients with severe general peritonitis. Eur J Surg 1997;163:61-66.
26. Madan AK. Use of ciprofloxacin in the treatment of hospitalized patients with intra-abdominal infections. Clin Ther 2004;26:1564-1577.
27. Marshall JC, Innes M. Intensive care unit management of intra-abdominal infection. Crit Care Med 2003;31:2228-2237.
28. Mazuski JE, Sawyer RG, Nathens AB, et al. The SIS guidelines on antimicrobial therapy for intra-abdominal infections: An executive summary. Surg Infect (Larchmt) 2002;3:161-173.
29. Mazuski JE, Sawyer RG, Nathens AB, et al. The SIS guidelines on antimicrobial therapy for intra-abdominal infections: Evidence for the recommendations. Surg Infect (Larchmt) 2002;3:175-233.
30. Krobot K, Yin D, Zhang Q, et al. Effect of inappropriate initial empiric antibiotic therapy on outcome of patients with community-acquired intra-abdominal infections requiring surgery. Eur J Clin Microbiol Infect Dis 2004;23:682-687.
31. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg Infect (Larchmt) 2010;11:79-109.
32. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: Guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010;50:133-164.
33. Montravers P, Lepape A, Dubreuil L, et al. Clinical and microbiological profiles of community-acquired and nosocomial intra-abdominal infections: Results of the French prospective, observational EBIIA study. J Antimicrob Chemother 2009;63:785-794.
34. Baquero F, Hsueh P-R, Bochicchio GV, et al. In vitro susceptibilities of aerobic and facultatively anaerobic gram negative bacilli isolated from patients with IAIs worldwide: 2005 results from SMART. Surg Infect (Larchmt) 2009;10:99-104.
35. Rossi F, Baquero F, Hsueh PR, et al. In vitro susceptibilities from SMART-2004. J Antimicrob Chemother 2006;58:205-210.
36. Linder JA, Huang ES, Steinman MA, et al. Fluoroquinolone prescribing in the United States: 1995-2002. Am J Med 2005;118:259-268.
37. Citron DM, Appleman MD. Comparative in vitro activities of trovafloxacin (CP-99, 219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections. Antimicrob Agents Chemother 1997;41:2312-2316.
38. Behra-Miellet J, Dubreuil L, Jumas-Bilak E. Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams. Int J Antimicrob Agents 2002;20:366-374.
39. Stein GE, Goldstein EJ. Review of the in vitro activity and potential clinical efficacy of levofloxacin in the treatment of anaerobic infections. Anaerobe 2003;9:75-81.
40. Wenzler S, Schmidt-Eisenlohr E, Daschner F. Comparative in vitro activities of three new quinolones and azithromycin against aerobic pathogens causing respiratory tract and abdominal wound infections. Chemotherapy 2004;50:40-42.
41. Edmiston CE, Krepel CJ, Seabrook GR, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 2004;48:1012-1016.
42. Goldstein EJ, Citron DM, Warren YA, et al. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2006;50:148-155.
43. Stein GE, Goldstein EJC. Fluoroquinolones and anaerobes. Clin Infect Dis 2006;42:1598-1607.
44. Thadepalli H, Chuah SK, Gollapudi S. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice. Chemotherapy 2008;50:76-80.
45. Schaumann R, Blatz R, Beer J, et al. Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coli. J Antimicrob Chemother 2004;53:318-324.
46. Liu CY, Huang YT, Liao CH, et al. Increasing trends in antimicrobial resistance among clinically important anaerobes and B.fragilis isolates causing nosocomial infections: Emerging resistance to carbapanems. Antimicrob Agents Chemother 2008;52:3161-3168.
47. Ambler J, Rennie R, Poupard J, et al. Determination of moxxifloxacin anaerobic susceptbility breakpoints according to the CLSI guidelines. Diagn Microbiol Infect Dis 2008;61:49-57.
48. Stein GE, Schooley S, Tyrrell KL, et al. Serum bactericidal activities of moxifloxacin and levofloxacin against aerobic and anaerobic intra-abdominal pathogens. Anaerobe 2008;14:8-12.
49. Lubasch A, Keller I, Borner K, et al. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 2000;44:2600-2603.
50. Wirtz M, Kleeff J, Swoboda S, et al. Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother 2004;53:875-877.
51. Stass H, Rink AD, Delesen H, et al. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother 2006;58:693-696.
52. Wacke R, Forster S, Adam U, et al. Penetration of moxifloxacin into the human pancreas following a single intravenous or oral dose. J Antimicrob Chemother 2006;58:994-999.
53. Mandell GL, Coleman E. Uptake, transport, and delivery of antimicrobial agents by human polymorphonuclear neutrophils. Antimicrob Agents Chemother 2001;45:1794-1798.
54. Pascual A, Garcia I, Ballesta S, Perea EJ. Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells. Antimicrob Agents Chemother 1999;43:12-15.
55. Rink AD, Stass H, Delesen H, et al. Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess. Clin Drug Investig 2008;28:71-79.
56. Solomkin J, Zhao YP, Ma El, et al. DRAGON study team. Moxifloxacin is non-inferior to combination therapy with ceftriaxone plus metronidazole in patients with communityorigin complicated intra-abdominal infections. Int J Antimicrob Agents 2009;34:439-445.
57. Fihman V, Bercot B, Mateo J, et al. First successful treatment of Nocardia farcinica brain abscess with moxifloxacin. J Infect 2006;52:99-102.
58. Shapiro MA, Sesnie JC, Desaty TM, et al. Comparative therapeutic efficacy of clinafloxacin in a Pseudomonas aeruginosa mouse renal abscess model. J Antimicrob Chemother 1998;41:403-405.
59. Ott SR, Allewelt M, Lorenz J, et al. German Lung Abscess Study Group. Moxifloxacin vs. ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection 2008;36:23-30.
60. Stass H, Kubitza D. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man. J Antimicrob Chemother 1999;43(suppl B):83-90.
61. Sullivan JT, Lettieri JT, Liu P, Heller AH. The influence of age and gender on the pharmacokinetics of moxifloxacin. Clin Pharmacokinet 2001;40(suppl 1):11-18.
62. Wispelwey B. Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Infect Dis 2005;41(suppl 2):S127-S135.
63. Hermsen ED, Hovde LB, Sprandel KA, et al. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2005;49:685-689.
64. Malangoni MA, Song J, Herrington J, et al. Randomized controlled trial of moxifloxacin compared with piperacillintazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006;244:204-211.
65. Brook I, Frazier EH. Aerobic and anaerobic microbiology in intra-abdominal infections associated with diverticulitis. J Med Microbiol 2000;49:827-830.
66. Weiss G, Reimnitz P, Hampel B, et al. AIDA Study Group. Moxifloxacin for the treatment of patients with cIAI, the AIDA study. J Chemother 2009;21:170-180.
67. Moxifloxacin [package insert]. Kenilworth, NJ: Schering-Plough Corporation, 2007.
68. Bartlett JG. Clinical practice. Antibiotic-associated diarrhea. N Engl J Med 2002;346:334-339.
69. Owens RC. Clostridium difficile-associated disease: Changing epidemiology and implications for management. Drugs 2007;67:487-502.
70. Johnson S, Samore MH, Farrow KA, et al. Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med 1999;341:1645-1651.
71. Hubert B, Loo VG, Bourgault AM, et al. A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Québec. Clin Infect Dis 2007;44:238-244.
72. Warny M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005;366:1079-1084.
73. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005;353:2442-2449.
74. Institut National de Santé Publique du Québec. Surveillance des diarrhées associées à Clostridium difficile au Québec. Bilan du 21 août 2005 au 19 août 2006. Available at www.inspq.qc.ca/pdf/publications/561-SurveillanceCDifficile-Aout2005-aout2006. pdf, accessed January 7, 2007.
75. Owens RC, Kruesmann F, Reiter C, et al. Comparative frequency of Clostridium difficile-associated diarrhea in Phase II and Phase III moxifloxacin clinical trials [poster 117]. Poster presented at the 7th European Congress of Chemotherapy and Infection, October 19-22, 2005, Florence, Italy.
76. Snydman DR, Jacobus NV, McDermott LA, et al. National survey on the susceptibility of Bacteroides fragilis group: Report and analysis of trends in the United States from 1997 to 2004. Antimicrob Agents Chemother 2007;51:1649-1655.
77. Golan YL, McDermott A, Jacobus NV, et al. Emergence of fluoroquinolone resistance among the Bacteroides species. J Antimicrob Chemother 2003;52:208-213.
78. Betriu C, Rodriguez-Avial I, Gomez M, et al. Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002). Diagn Microbiol Infect Dis 2005;53:221-223.
79. Oteo-Iglesias J, Alos JI, Gomez-Garces JL. Increase in resistance to new fluoroquinolones from 1998 to 2001 in the Bacteroides fragilis group. J Antimicrob Chemother 2002;50:1055-1057.
80. Papaparaskevas J, Pantazatou A, Katsandri A, et al. Moxifloxacin resistance is prevalent among Bacteroides and Prevotella species in Greece. J Antimicrob Chemother 2008;62:137-141.